Company Overview and News

 
Teranga Gold Concludes $165 Million Development Finance Facility with Taurus

2018-04-16 globenewswire
TORONTO, April 16, 2018 (GLOBE NEWSWIRE) -- Teranga Gold Corporation ("Teranga" or the "Company") (TSX:TGZ) (OTCQX:TGCDF) is pleased to announce that it has concluded an agreement with various funds managed by Taurus Funds Management Pty Ltd. (“Taurus”) in respect of its previously announced secured development finance facility (the “Facility” and the “Facility Agreement”). The Facility includes the following:
Upvote Downvote

 
Teranga Gold Reports High-Grade Gold from Phase 2 Drilling at Golden Hill’s C-Zone Prospect

2018-04-16 globenewswire
TORONTO, April 16, 2018 (GLOBE NEWSWIRE) -- Teranga Gold Corporation ("Teranga" or the "Company") (TSX:TGZ) (OTCQX:TGCDF) is pleased to announce that its phase 2 diamond drill program at the C-Zone prospect on the Golden Hill property in Burkina Faso, West Africa has returned near surface and deeper high-grade gold intersections.
Upvote Downvote

1
Gold Mining Bull: Top News And Month In Review

2018-04-04 seekingalpha
Here's a monthly recap of the top news in the gold mining sector, including drill results, takeover announcements and other relevant updates, to keep readers up-to-date on news in the sector. Here's my update for February if you missed it.
Upvote Downvote

 
Boss Resources’ earn-in partner hits high-grade gold in West Africa

2018-03-23 proactiveinvestors.com.au
Boss Resources Ltd (ASX:BOE) earn-in partner Teranga Gold Corporation (TSX:TGZ) has received high-grade gold hits from drilling at Golden Hill Gold Project in West Africa.
Upvote Downvote

 
Teranga’s Golden Hill Drill Program Intersects High-Grade Gold and Expands Mineralized Zones at Peksou and Ma Prospects

2018-03-22 globenewswire
Results include 6.78 g/t gold over 11 metres and 2.09 g/t gold over 27 metres at Peksou, and 6.46 g/t gold over 5 metres and 6.39 g/t gold over 6 metres at Ma North
Upvote Downvote

 
BRIEF-Teranga Gold Receives Commitment Letter For $165 Mln In Secured Debt Financing To Bring Its Second Gold Mine Into Production

2018-03-12 reuters
* TERANGA GOLD RECEIVES COMMITMENT LETTER FOR $165 MILLION IN SECURED DEBT FINANCING TO BRING ITS SECOND GOLD MINE INTO PRODUCTION
Upvote Downvote

 
Teranga Gold - I Am Optimistic In The Medium Term

2018-03-07 seekingalpha
In the medium term Teranga share prices should be supported by the company's largest shareholder; since November 2017 this shareholder has purchased 2.05 million shares and is still buying.
Upvote Downvote

 
Teranga Gold: Get By With A Little Help From Gold Prices

2018-03-05 seekingalpha
Teranga Gold has an achievable organic growth pipeline supported by strong free cash flows from current operations.
Upvote Downvote

4
Gold Mining Bull: Top News And Month In Review For February 2018

2018-02-28 seekingalpha
Here's a monthly recap of the top news in the gold mining sector, including drill results, takeover announcements and other relevant updates; the purpose is to keep readers up-to-date on news in the sector. Here's my update for January in case you missed it.
Upvote Downvote

 
Teranga Gold Corporation 2017 Q4 - Results - Earnings Call Slides

2018-02-26 seekingalpha
The following slide deck was published by Teranga Gold Corporation in conjunction with their 2017 Q4 earnings call.
Upvote Downvote

 
Teranga Gold's (TGCDF) CEO Richard Young on Q4 2017 Results - Earnings Call Transcript

2018-02-23 seekingalpha
Teranga Gold Corp CDA (OTCQX:TGCDF) Q4 2017 Earnings Conference Call February 23, 2018 8:30 AM ET
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...